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With the emergence of electronic medical records
and patient portals, patients are increasingly able to
access their health records, including laboratory
reports. However, laboratory reports are usually
written for clinicians rather than patients, who may
not understand much of the information in the report.
While several professional guidelines define the
content of test reports, there are no guidelines to
inform the development of a patient-friendly laboratory
report. In this Opinion, we consider patient barriers
to comprehension of lab results and suggest several
options to reformat the lab report to promote
understanding of test results and their significance
to patient care, and to reduce patient anxiety and
confusion. In particular, patients’ health literacy, genetic
literacy, e-health literacy and risk perception may
influence their overall understanding of lab results and
affect patient care. We propose four options to reformat
lab reports: 1) inclusion of an interpretive summary
section, 2) a summary letter to accompany the lab
report, 3) development of a patient user guide to be
provided with the report, and 4) a completely revised
patient-friendly report. The complexity of genetic and
genomic test reports poses a major challenge to patient
understanding that warrants the development of a
report more appropriate for patients.* Correspondence: susanne.haga@duke.edu
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Genetic and genomic testing is expected to grow sub-
stantially, shifting from esoteric to routine laboratory
testing [1,2]. It is estimated that more than $5 billion is
currently spent on genetic and genomic testing in the
United States, and this is projected to increase to $25
billion by 2021 [3]. Furthermore, the complexity of test-
ing will increase with the expanded use of comprehen-
sive genomic testing platforms such as whole genome
sequencing and chromosomal microarray testing [4]. Con-
current with advances in molecular testing, patient access
to lab reports is increasingly available through patient
health portals and electronic medical records (EMRs).
Greater access to test results may help to promote more
effective and satisfactory patient-provider engagement, pa-
tient understanding, shared decision-making, and adher-
ence with clinical recommendations [5-16]. However, a
lack of patient comprehension of genetic and genomic in-
formation may substantially limit the benefits of patient
access to their reports, as has been shown with other types
of medical information [17-19]. For example, patients who
do not understand their health information may show
lower engagement and satisfaction with their care [20],
display poor adherence to recommended interventions
[21-25], and experience anxiety [13]. Furthermore, acces-
sing genetic or genomic lab reports may increase patient
anxiety due to confusion about the purpose and outcomes
of testing [26], and thus adversely influence their medical
care.
Little guidance is available on how best to present gen-
etic or genomic lab results in an understandable format
and at an appropriate reading level for patients. With re-
spect to health information in general, Tang et al. [18]
recommend that it must be presented ‘in ways that en-
able the individual to understand and to act on the
information contained in the record’. Although the
readability of test reports has not been specificallytd. The licensee has exclusive rights to distribute this article, in any medium, for 12
, the article is available under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
Box 1. Current content of molecular test reports [32,44]
 Patient name/date of birth
 Date and (if applicable) time of specimen collection/receipt in
lab
 Referring physician/authorized person who ordered test
 Test performed/indication for testing
 Test background
 Test methodology, including nucleic acid targets of test
 Test results
○ DNA variants
▪ Individual variant interpretations
▪ Variants of unlikely clinical significance
 Interpretation of test results/summary
 Test limitations
 References to literature (if applicable)
 Recommendations
o Follow-up care/testing
o Genetics consultation (where appropriate)
 Implications of test results for relatives or family members
who might benefit (if applicable)
 Statement indicating that test results and interpretation are
based on current knowledge and technology
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not been intended for patient use), analysis of health
educational materials intended for patients shows that
many are not suitably written for patients, highlighting
the challenges of writing for a lay audience [27-29]. Sev-
eral ongoing efforts have evaluated the content of reports
from genetic testing, particularly for clinical genome se-
quencing [30-32]. However, these recommendations are
generally focused on the needs of the clinician, although
patient preferences were recognized as an important
element in the reporting of incidental findings [31].
With increased patient access to lab reports, now is the
time to consider the development of a patient-friendly re-
port format to improve patient comprehension and en-
gagement. In addition, as more and more non-geneticist
providers with varying levels of knowledge and experience
are ordering genetic and genomic testing, a patient-
friendly reporting format may also benefit clinicians. Early
use of whole genome sequencing indicates that the time
required for counseling is substantial, with reports of
post-test sessions of 2 to 3 hours [33-36]; a patient-
friendly lab report may help reduce the time needed to ex-
plain test results, leaving more time instead to discuss the
significance of the results for health care, and may in-
crease the use and feasibility of testing. In this Opinion,
we review the current reporting formats, discuss potential
patient barriers to comprehension, and propose several
options to reformat genetic and genomic lab reports to
promote patient comprehension and engagement.
Current genetic and genomic test reporting
formats
In the United States, the content and availability of test
result reports are regulated by federal regulations (42
CFR 493.1291) and professional guidelines [37-44]. The
lab report must include information about the patient,
ordering physician, specimen collection, test method, re-
sults and interpretation in a format and language under-
standable to a general practice physician (Box 1). Overall,
genetic and genomic lab reports tend to be very technical
in nature due to the complex testing platforms used and
variable test outcomes. For example, reporting genetic
variants may include information about the gene (such as
gene name, zygosity, cDNA nomenclature, rs number)
and protein (protein nomenclature), as well as the
phenotype or result interpretation (for example, poor
metabolizer) [45]. Clinical genome sequencing lab re-
ports may differ somewhat from more traditional, single
gene test results given the comprehensive nature of se-
quencing. Current guidelines suggest prioritization of test
results based on the patient’s phenotype, determination of
which variants are included in the report (for example, op-
tional inclusion for variants with no known disease associ-
ation), and reporting of incidental findings [32,46].Although the content of reports is regulated, the for-
mat and presentation are not, and are largely decided by
the lab performing the test. In some reports, a summary
statement of the results is included in the section follow-
ing the patient and provider information at the top of
the report. The summary statement may start with the
words ‘positive’ or ‘negative’, followed by a description of
the specific genetic change identified as a likely cause for
the patient’s condition (for example, ‘Positive - an estab-
lished cause of the reported phenotype was identified’).
Additional information, such as the biochemical, mo-
lecular or cellular effect of the change may then be in-
cluded in an expanded results section. Regarding the
interpretation and follow-up sections, the scope of infor-
mation provided by different labs can also vary dramatic-
ally. Some labs simply list the acquired mutations using
standard nomenclature and defer all interpretation to the
care provider receiving the result. Other labs provide ref-
erences and treatment recommendations based on the
mutations identified. In all but a few, very rare cases, re-
ports are written and formatted for health providers.
This heterogeneity of reporting formats may influence
clinical interpretation, given the differing levels of famil-
iarity with genetic and genomic tests among ordering
clinicians [47-51]. Studies of health providers’ satisfac-
tion and perception of the utility of clinical lab reports
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the content, use of ambiguous terminology, complexity
of results, unclear interpretation of results, and lack of
follow-up recommendations [30,52-55]. In addition, the
common use of scientific or medical jargon to describe
the testing methodology, results (for example, heterozy-
gous mutation, conserved splice site, splicing, alleles,
missense mutation), interpretation (for example, ‘this
mutation most likely disrupts a conserved splice site and
abrogates normal splicing, causing severe defects in
LMNA protein production’) and follow-up (for example,
‘maternal metaphase FISH analysis utilizing interval spe-
cific BAC probes are recommended to investigate the
suspected familial rearrangement’) may pose challenges
to comprehension for both providers and patients.
Until recently, genetic test results were most often ver-
bally communicated by a clinician or genetic counselor
[56-61], and the patient did not receive a copy of the re-
port unless requested. However, US health information
technology regulations currently require patient elec-
tronic access to their records (Stage 2, Core Measure 7)
[62,63], and many health systems have implemented
enterprise-wide EMR systems that have a fully functional
patient portal enabling access to documents including
lab reports [64]. Specifically, for a clinical or health
organization to meet current meaningful use require-
ments for EMRs, 50% of all patients much be given
timely access (within 4 days) to their health information
after their clinical encounter, including lab results. Some
clinicians may have exceptions for information that can
only be released to the EMR after the patient has been
contacted by their provider (after a 4-day window). Gen-
etic testing may be considered a type of information that
is too complex to release directly to the patient without
interpretation by a clinician or geneticist first. Alterna-
tively, patients may request a copy of the report directly
from the testing lab [65].
Patient barriers to comprehension of genetic and
genomic test reports
While several studies have explored the communication
of genetic test results to patients, fewer studies have
considered the patient experience of the actual lab re-
port [26]. Important predictors of patients’ experiences
include their understanding of the purpose and out-
comes of testing, and how the results may impact diag-
nosis or medical management, their satisfaction and,
ultimately, health outcomes [66,67]. We describe several
barriers that may pose challenges to patient comprehen-
sion of genetic and genomic test reports, including health
literacy, genetic literacy, e-health literacy (for results re-
ported via an online patient portal) and risk perception.
Health literacy is broadly defined as ‘a constellation of
skills, including the ability to perform basic reading andnumerical tasks required to function in the health care
environment’ [68]. Low health literacy may affect the
ability of patients to comprehend and/or utilize genomic
risk information to reduce disease risk and participate in
healthcare decisions [69-71]. The ‘readability gap’- the
disparity between the language used in health docu-
ments and the reading level of the user - has been re-
ported to be a major barrier to patient comprehension
[72-77]. In addition, low numeracy skills have been asso-
ciated with worse perceived self-efficacy and self-
management behaviors [78], and contribute to health
disparities [79]. As many genetic and genomic tests may
include a numeric risk or probability of developing a
given phenotype, communication and comprehension of
risk will be a major challenge for many health providers,
including genetic counselors [80] and patients, respect-
ively. Presentation of risk in multiple formats (text, nu-
merically, pictorially) [81] and assessment of patient
comprehension through teach-back techniques are often
recommended [82]. Novel technologies such as avatars
and personalized graphics are also being explored to im-
prove patient comprehension [83].
Genetic literacy has been defined as ‘sufficient know-
ledge and appreciation of genetics principles to allow in-
formed decision-making for personal well-being’ [84].
Unfamiliarity with genetic concepts and terms may pose
barriers to understanding of or appropriately acting upon
genetic test results [85-87]. For example, unfamiliarity
with gene nomenclature, symbols denoting alleles (for in-
stance, *1), and genetic terminology (such as carrier, het-
erozygosity) will likely exacerbate patient confusion. The
use of genetic terminology or jargon may also pose
challenges for providers and it has been recommended
that reports be written in an understandable language
for non-geneticist health providers [44,88].
As more health systems transition to EMRs with pa-
tient portals, e-health literacy may pose an additional
challenge for patients. E-health literacy refers to the abil-
ity to ‘seek, find, understand, and appraise health infor-
mation from electronic sources and apply the knowledge
gained to addressing or solving a health problem’ [89].
In general, patient experiences with EMRs [90] and on-
line health communication [91] have been reported to
be positive. Accessing health information online is con-
venient and enables the patient to control the pace and
amount of information consumed [92]. Interactive com-
puter programs have also been found to be more effective
than standard genetic counseling for increasing knowledge
of genetic testing [93,94]. Comfort with online genetics
communication has been associated with previous online
health information seeking, a healthy lifestyle and a posi-
tive attitude towards genetics [95]. However, limitations in
e-health literacy may affect a patient’s likelihood to access
online resources and lab reports through a health portal.
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eracy, genetic literacy and e-health literacy), patients’ un-
derstanding of the actual test results may be affected by
their perception of risk [96,97], which is based on a
combination of factors, including their motivational and
emotional state, underlying expectations, and family
members’ experience with an illness [98-101]. For ex-
ample, lifetime risk estimates based on a positive genetic
test result (a causative mutation is detected) do not ap-
pear to substantially influence risk perception compared
to risk estimates based on family history [102,103]. How-
ever, risk estimates based on a negative test result (a
disease-causing genetic mutation is not detected) may
lead to differences in risk perception compared to risk
estimates based on family history [102,103]. The ‘mean-
ing’ or implication of a test result is further framed by
ethnicity and culture [104]. Many health behavior models
emphasize the importance of patients’ perception of risks
[105]; thus, an accurate understanding of their test result
may encourage patients to revise these perceptions, which
may lead to improved compliance with clinical follow-up
or medications [106,107].
Moving towards a patient-friendly test reporting
format
The development of patient-friendly lab test reports will
require an understanding not only of what types of in-
formation patients desire to learn and need to under-
stand to interpret the test result, but also what
information will be most helpful in influencing the ap-
propriate utilization of results [6] and how best to
present that information to optimize patient comprehen-
sion. However, few studies have explored patients’ needs
with respect to the development of patient-friendly health
records [17,20], and only one study has described efforts
to develop a patient-friendly pathology report [108]. Kesel-
man et al. [17] reported that patients desired help to
understand the purpose of the test, the reporting range or
units of the results reported, and the interpretation of re-
sults. Elder and Barney [20] reported that patients’ under-
standing of the purpose of testing, the actual lab results
(with a description of desired values), and the significance
of the result for their care was critical to their satisfaction.
An important consideration when revising lab reports
is the amount of education and information given to pa-
tients prior to testing. Pre-test communication is an im-
portant part of the overall testing process, as it prepares
patients for the type of possible results from genetic or
genomic testing (including inconclusive results and inci-
dental findings) and how results may be used to inform
their care. As a result, pre-test communication can re-
duce the time and need to provide detailed background
information about testing when communicating results or
in the lab report. However, due to the lack of standardprotocols or accepted patient educational materials for
genetic and genomic testing, and depending on the pro-
vider and their access to genetics experts, the extent of
pre-test communication provision may vary widely. In
addition, while many different patient resources have been
developed to promote awareness and inform decision-
making, particularly for cancer susceptibility testing [109],
disparities between patients’ reading level and the re-
sources continue to pose major challenges [110]. Labs
could encourage pre-test education by requiring signed
patient consent forms or providing educational materials
with marketing materials or lab requisition forms.
Lab professionals can serve as an integral part of the
healthcare team by promoting effective communication
with patients via their reports. The identification and
curation of reliable information to aid in the compre-
hension of test results is an essential function of clinical
lab professionals. This responsibility can no longer be de-
ferred to the ordering physician. An understandable lab
report will prepare the patient to engage in meaningful
discussions with their provider about their care, optimiz-
ing limited time and healthcare resources. Many of the
principles applied to the development of current lab re-
ports for clinicians could be applied to the development of
patient-friendly lab reports, including synoptic reporting
frameworks (or partitioning the report into uniform, easy-
to-find sections) [52] and patient narratives [53].
On the basis of a review of the literature and of our
collective experiences, we propose four possible options
to improve genetic and genomic lab reports. Each of the
proposed options is intended to address the patient bar-
riers of health literacy, genetic literacy and e-health liter-
acy and can be adopted for paper or electronic reports
to accommodate differing health systems and patient
preferences. Figure 1 provides a mock-up of each of the
options for the pharmacogenetic test for KRAS mutation
analysis. Table 1 includes an overview of the benefits
and challenges of each recommended option.
Option 1: Interpretive summary
Since the test result/finding is the crux of the report,
one format option is to add a boxed results summary
section (‘interpretive summary’) on the first page for pa-
tients, while keeping the remainder of the report in its
current format. Prominently displaying key information
in a language that is understandable can help patients to
identify more easily the section(s) of the report of inte-
rest to them and reduce frustration. The American Col-
lege of Medical Genetics and Genomics (ACMG) has
recommended that a ‘succinct, high-level interpretive
result should be provided at the start of the interpret-
ation’ for testing results from next-generation sequen-
cing [32]. However, the proposed ACMG summary is
intended for providers and we suggest that a simple,
Figure 1 (See legend on next page.)
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Figure 1 Mock-up reports of the four proposed options for the pharmacogenetic mutation analysis test of the KRAS gene to inform
treatment decisions for colorectal cancer patients [111-113]. (a) Option 1: test report with interpretative summary box written in patient-
friendly language describing the test, test result, and interpretation. (b) Option 2: summary letter with more extensive description of the test and
test result in patient-friendly language. (c) Option 3: patient user guide to accompany the test report to help patients navigate and understand
sections of the test report. (d) Option 4: first page of a completely patient-friendly lab test report written in patient-friendly language. Please note
that these sample reports are not actual clinical reports. Note, for option 2, that the Flesch-Kincaid Reading Ease [114] score is 51 (on a scale from
1 to 100), corresponding to a 9th grade reading level. For option 4, the Flesch-Kincaid Reading Ease score is 56 (on a scale from 1 to 100),
corresponding to a 9th grade reading level. However, if the names of the drugs are removed, it decreases to a 7th to 8th grade reading level.
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for patients could include a brief description of the test
performed, test result, result interpretation and clinical
recommendations [26,91]. With this option, the patient
can immediately view his or her results, without wading
through a multi-page report. Additionally, clinicians may
choose to incorporate the interpretive summary text in
their encounter note within the EMR, to which patients
may have access. The content and format of the summary
could be standardized to promote familiarity and ease of
use for patients, regardless of the type of test performed.
The corresponding section in the lab report could be ref-
erenced in the interpretive summary to direct patients to




· Includes short patient-friendly summary of test per
results, interpretation and clinical recommendation
· Easy for patients to find important results in multi-
report
· Requires minimal effort from lab
· May aid providers as well as patients in understand
results




· Includes an overview of the information in the resu
in a patient-friendly letter
· There is already an established practice in place (fo
genetic counselors writing letters)
· Letters are personalized for each patient
Option 3: Patient user
guide
· Includes an explanation of each section of the rep
patient-friendly language
· Can assist patients in use of patient portal to review
· Providing user guide prior to testing may enable p
be prepared for result
· Would require minimal effort for each individual pa
Option 4: Complete
patient-friendly report
· The entire report is written in patient-friendly langu
· May aid providers as well as patients in understand
· Providing a patient-friendly report in addition to a
report may satisfy patients with higher literacyexample, ‘see Section Option 1: Interpretive summary’).
Overall, the effort required to add a single new section
would be minimal, less disruptive for clinicians as the
rest of the report would remain the same, and would fa-
cilitate patients’ ability to quickly locate information of
greatest interest while also continuing to provide access
to the full report for patients interested in additional
information.
Option 2: Summary letter
Similar to an interpretive summary, a summary letter or
patient letter could be appended to the clinical lab report,
providing more extensive information about testing and









lts report · Would require an EMR to work most effectively
r example, · Requires an extensive amount of time to set up
templates/standardized text
· Requires additional time for each patient
· Requires collaboration between lab and clinician to write
detailed letter
ort in · Would benefit from having an EMR in place
results · Requires an extensive amount of time to set up templates
atients to · Only text that will be patient-friendly is the guide; text
within the report may still be difficult to understand
tient
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marizing the test result and subsequent discussion in the
counseling session [115], but no data are available regard-
ing how prevalent the practice is or if letters are only sent
for certain results (for instance, if letters are only sent to
patients with new diagnoses). Labs could prepare a sum-
mary letter intended for the patient that would be sent
with the test report; the provider may have the option to
add information about interpretation and follow-up, and
could then forward the letter to the patient or upload it to
the patient’s EMR. A shared EMR, such as between a lab
and a clinician within a hospital or academic medical cen-
ter, would enable providers to insert additional informa-
tion to contextualize the results before sending the letter
to the patient. The template of the patient letter could in-
clude a description of the purpose of the test, the test re-
sult, and any follow-up recommendations (for example,
follow-up office visit, additional testing) [115-117]. For
test results with potential psychological effects, a sec-
tion on coping-related strategies could also be in-
cluded [115,118]. The primary challenge will be to
ensure that letters are written in a language under-
standable to the patient [119,120], with limited use of
medical jargon or concepts [121,122]. This approach is
being used to communicate pharmacogenetic test re-
sults to patients in a study at St Jude Children’s Re-
search Hospital; a letter communicating the child’s test
results is sent to parents along with an information
fact sheet [123], and the patient’s specific findings and
recommendations are inserted into a letter template
using patient-friendly language. Use of a patient letter
could supplement the patient-provider discussion of test
results and serve as a written record of testing that pa-
tients may share with other providers or family members.
Option 3: Patient user guide
To assist patients with navigating a genetic or genomic
test report, which can often span several pages, a ‘user
guide’ could be developed (for example, ‘How to Read
Your Test Report’). As often provided for a range of
consumer products, the user guide could give a general
explanation of each section of the test report. The user
guide would resemble a test report and include an ex-
planation of each section in patient-friendly language
with a sidebar or call-outs (for example, ‘this section de-
scribes how the test was performed’). If the format of
the test report was standardized, a single user guide
could be developed and sent with each lab report,
thereby substantially reducing the effort required by the
lab to develop the guide. A copy of the user guide could
also potentially be given to the patient when testing is
ordered, during pre-test communication, to familiarize
and prepare patients on how to read the lab report. To
assist patients with limited e-health literacy, a printeduser guide could provide tips on how to use online tools
provided in the electronic version of the report or provide
instructions on how to access the lab report through the
lab’s website, if available. Additionally, for electronic lab
reports, the user guide could be integrated into the online
report; for example, each section heading of the report
could be linked to or have a pop-up explanation of that
section. Patient understanding of either paper or elec-
tronic lab reports could be further improved with aux-
iliary learning aides, explanations, definitions or links
to additional resources [124,125], appended or inte-
grated into the lab report. For example, the US Centers
for Disease Control and Prevention recommends that
if no mutation is detected, the report should state ‘no
mutation detected’ rather than ‘normal’ [44]. However,
patients may interpret this finding as a negative result,
when in fact it may just rule out one possible gene for
a genetically heterogeneous disease, or rule out one of
many possible differential diagnoses. Therefore, pro-
viding a detailed description of the meaning and impli-
cation of the result that is understandable to the patient is
important. The US National Human Genome Research
Institute has developed a glossary that could be linked to
the test report or included in the user guide [126]. By
directing patients to specific written or online resources,
patients will avoid the additional challenge of identifying
credible resources to decipher the information within the
lab report.
Option 4: Complete patient-friendly report
Developing a patient-friendly version of the entire report
is a fourth option that would probably provide patients
with the most information, but would require extensive
work for labs to develop one for each test. The format of
the report, including section headings such as results,
methodology and interpretation, may remain the same
but the text or figures in each section would need to be
revised to be more understandable to patients. Clinicians
(as well as some patients) may still desire to have the de-
tailed, more formal report and, therefore, both a patient
and standard version of the test report may need to be
available. Sending two versions of a test report may be
preferred by patients of high health literacy or educa-
tional status, who may view the patient-friendly version
as less credible or unable to meet their informational
needs. Like the patient letter option, a completely revised
patient-friendly report could serve as a record for patients
to share with other providers and family members.
Other options and considerations
We have presented just four possible options for im-
proving the format of genetic and genomic lab test re-
sults for the benefit of patients. There are undoubtedly
other possible formats, as well as educational aides (for
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comprehension that are not discussed here. With the in-
creased use of EMR and online portals, there are even
greater possibilities for improvement, such as enhancing
interface design to include links to additional informa-
tion (for example, glossary, other websites) to promote
comprehension and usability [17,127-129]. Using an on-
line system for reviewing results may also present the
opportunity to create interactive reports that will further
engage the patient and potentially promote increased
understanding and recall.
Currently, lab reports for genetic and genomic testing
are primarily text based, and are written in a language
beyond the reading level of most patients. All of the pro-
posed options will require the use of plain language or
consumer health vocabularies [17,128,130] to achieve
the 6th to 7th grade reading level recommended for pa-
tient health materials [129] and minimize potential mis-
interpretation of results. Additionally, presenting results
in numeric and non-numeric text [131], as well as in
graphical modes, may also improve patient comprehen-
sion [132,133]. Tables may be challenging for some pa-
tients to interpret [134] and a summary or synopsis may
be helpful to explain the significance of the information
for the patient.
The burden on labs to reformat test reports must also
be considered. Lab expenses related to re-formatting of
reports, information technology and increased patient
engagement from requests for results may be recovered
through preparatory fees [19] or clinical consultation
fees for patients requiring further assistance to under-
stand the lab report (such as a phone consultation).
Prior to the broad implementation of patient-friendly lab
reports, assessments of providers’ preferences for a sin-
gle lab report or separate reports (patient and provider)
as well as the impact of the patient-friendly report on
practices will also be needed. These considerations will
affect which format option will be best for the lab, the
clinicians, and the patient population they serve. Each
option has unique benefits and challenges to its imple-
mentation (Table 1). Of the formats we have proposed,
option 1 would probably require the least amount of effort
to develop and implement, whereas option 4 would pro-
bably require the most. Both options 2 and 3 would pro-
bably require a similar degree of effort to develop and
implement, although electronic reporting of lab results
may facilitate implementation of option 3. Conversely, op-
tion 3 would be an independent, stand-alone aid to assist
patient navigation of the lab report, whereas options 2 and
4 would need to be individualized for each patient’s result.
Conclusions
Patients are increasingly able to access their lab reports
via EMRs and patient portals or directly upon requestfrom the testing lab. However, patients may have difficulty
understanding genetic and genomic lab reports due to low
health, genetic or e-health literacy and complexity of the test
result, and therefore, may benefit from a re-designed report-
ing format. We have proposed four options for consideration
to reformat genetic and genomic lab reports to promote pa-
tient comprehension: inclusion of an interpretive summary,
a summary letter, a patient user guide, or a patient-friendly
version of the entire report. The proposed formats should be
developed using patient-friendly language and include non-
text presentations of the results to improve comprehension
and utility for patients with varying levels of literacy.
It will be important to find the appropriate balance of
meeting patient needs with limiting disruption to pro-
vider practice and burden on testing labs. The develop-
ment of patient-friendly formats would not be impacted
by current regulations for lab reporting if the required
content is included in the current reporting format for
providers or within the patient-friendly version. Before
patient-friendly lab reports can be developed, research
will be needed to assess patient needs and preferences
for which information is included, how it is presented
and organized, comprehension, impact on patient behav-
iors and patient satisfaction. Although the clinicians’ role
as interpreter of results and provider of follow-up services
will continue to be an integral part of genetic and genomic
testing to contextualize the results in light of the individ-
ual patient’s clinical history, with patients’ increased access
to results, it is important to consider their needs as well.
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